Navigation Links
Similarities in imaging the human body, Earth's crust focus of conference at UH
Date:10/29/2008

HOUSTON, Oct. 29, 2008 Whether it's in the human body or under the Earth's crust, modeling the unseen involves many similar techniques. Physicians and geologists will be meeting at the University of Houston to discuss just how much they have in common.

Through a partnership between UH, M.D. Anderson Cancer Center (MDACC) and Apache Corporation, experts in biomedical and seismic imaging will gather to explore the potential for cross-collaboration in imaging. The UH Imaging Symposium will be sponsored by Apache Corp., an oil and gas exploration company. It will be held from 8 a.m. to 5 p.m., Thursday, Nov. 6 at UH in the Rockwell Pavilion of the M.D. Anderson Library. The event is free and open to the public.

The symposium will feature lectures by 16 leading experts from UH and MDACC, as well as industry leaders in the areas of oil and gas exploration and geophysics. This event will provide a platform for representatives from different disciplines to discuss shared challenges and offer novel theories to their peers for addressing them. The symposium's goal is to identify opportunities for cross-fertilization of ideas between biomedical and seismic imaging, resulting in new theories and paradigms to share among all imaging professionals, regardless of the field.

Six UH faculty and three MDACC researchers will deliver lectures during the conference. Joining them in the list of presentations will be various experts from Apache Corp., ExxonMobil Corp., Paradigm Geophysical, St. Luke's Health Care System, TGS-NOPEC Geophysical Co. and Schlumberger/WesternGeco. While the symposium's lectures will be technical in nature, the audience is expected to consist of a wide-ranging cross section of faculty, professionals and students in the areas of geology, geophysics, engineering, medicine and health. Topics to be addressed include everything from visualizing blood flow and cell imaging to well performance and how seismic imaging is
'/>"/>

Contact: Lisa Merkl
lkmerkl@uh.edu
713-743-8192
University of Houston
Source:Eurekalert

0

GOOD

Page: 1 2

Related biology news :

1. Of mice and men: similarities between skeletons of both
2. Purdue research finds similarities in dog, human breast cancer pre-malignant lesions
3. Telepathic genes recognize similarities in each other
4. Small animal imaging facility is big boon to research
5. New thoracic imaging approach can pinpoint underlying venous problems
6. Quantitative PET imaging finds early determination of effectiveness of cancer treatment
7. PET/CT imaging proves golden for detecting cancer in children
8. NSF awards Williams funding for high-speed imaging faciltity
9. Cognitive, genetic clues identified in imaging study of alcohol addiction
10. Radioactive understudy may aid medical imaging, drug development
11. Carnegie Mellon scientists develop fluorescent proteins for live cell imaging, biosensor design

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/4/2009)... N.Y., Oct. 21 What,s the cost of ... accidental death resulting from prescription medi...ood intentions, however, may be unaware that the l...ir teens from the ticking timebomb of prescription...n premium-quality medical supplies, has formed an ...
(Date:11/4/2009)...N.J., Oct. 26 BIO-key In...ader in finger-based biometric identification soft...tions at the AABB TXPO conference being held at th... 2009. BIO-key will provide hands-on product demon...echnology in booth #424. Also, at 5 PM on Monday, ...
(Date:11/4/2009)...PEL HILL Scientists at the University of North Ca...niversity of California, San Francisco have develo...ct new target diseases for existing drugs. , The... compares how similar the structures of all known ...ers -- known as ligands -- of disease targets with...
Breaking Biology News(10 mins):MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 2MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 3BIO-key(R) International Exhibiting at AABB TXPO 2Study points to new uses, unexpected side effects of already existing drugs 2EFT BioTech Holdings Inc s Sea Vessel Completes Inaugural Passenger Voyage Across the Taiwan Strait 12850 1EFT BioTech Holdings Inc s Sea Vessel Completes Inaugural Passenger Voyage Across the Taiwan Strait 12850 2EFT BioTech Holdings Inc s Sea Vessel Completes Inaugural Passenger Voyage Across the Taiwan Strait 12850 3Bion Announces Approval of New U S Patent that Broadens Protection for the Companys Livestock Waste Environmental Treatment Processes 12848 1Bion Announces Approval of New U S Patent that Broadens Protection for the Companys Livestock Waste Environmental Treatment Processes 12848 2Cosmetic surgery appeals to men women with appearance based rejection sensitivity 50413 1Cosmetic surgery appeals to men women with appearance based rejection sensitivity 50413 2
...ancer survivors might one day avoid the prospect o...nstead for an approach that would involve using st...rsity of Pittsburgh researchers who are studying t... new breast tissue. , In animal models, the resea...ved stem cells that are seeded onto microscopic sc...
...s of increased plant respiration in response to hi...d as they have not taken into account plants, abil... researchers from Oak Ridge National Laboratory. ,...ence, a team led by Tony King cites ORNL findings ...e stored in plants and soil with the acclimation o...
...g gene first identified in a cabbage-eating moth m...ative to viruses for gene therapy, researchers say...-characterized jumping genes, or transposons, to i...esired change, such as making the cell resistant t...e piggyBac transposon was five to 10 times better ...
Other Biology News:Fat stem cells being studied as option for breast reconstruction 2Plants' role in global warming re-examined 2Jumping gene could provide non-viral alternative for gene therapy 2Jumping gene could provide non-viral alternative for gene therapy 3
(Date:11/6/2009)...November 6 EUCODIS Bioscience, a c... marketing enzymes for the,chemical industry annou...eement with Bio Sidus, the leading biopharmaceutic...ent gives EUCODIS Bioscience exclusive access - fo..., proprietary collection of,psychrophilic bacteria...
(Date:11/6/2009)...wswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:O...oday announced updated results from a Phase II stu...comas metastatic to the lung in a poster presentat...Society Meeting held in Miami Beach, Florida, from...itled "A Phase II Study of Intravenous REOLYSIN (W...
(Date:11/5/2009)... hybrid . . . , Fuel economy ratings for the n...he www.fueleconomy.gov web site, which Oak Ridge...he U.S. Department of Energy and the U.S. Environm...es on the best fuel economy list are hybrid electr...way). "This list proves that hybrids have gone mai...
(Date:11/5/2009).... 5 DSM Pharmaceutical Products to...iance with Galenix, Saint Jean D,Illac, France, wh...ufacturing partner for Galenix commercial products...laborate on business development opportunities co-...d on the strength of Galenix in drug product devel...
Breaking Biology Technology:EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 2November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 3DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3
...Conn. The State of Connecticut,s highest honor fo...gy, was presented this year to Yale Professor Tso...nductors. , The Connecticut Medal of Technology...ducation and the Connecticut Academy of Science a...th the Connecticut Medal of Science and is designe...
...10 Cardium Therapeutics,(Amex: CXM ) today repor...,quarter ended September 30, 2008, and outlined re...units: (1) InnerCool Therapies, (2) Tissue Repair,...http://www.newscom.com/cgi-bin/prnh/20051018/CARDI...es, Inc. The Company recently announced 510(k) cl...
... constant currency revenue growth of 12.9 percent,...rcent, constant currency), and improving profita... - Management reaffirms annual financial guidance... Hill-Rom Holdings,Inc. (NYSE: HRC ), announced u...uarter ended September 30, 2008 -- the second quar...
Other Biology Technology:Yale professor T.P. Ma awarded the Connecticut Medal of Technology 2Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 2Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 3Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 4Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 5Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 6Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 7Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 8Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 9Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 10Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units 11Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 2Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 3Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 4Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 5Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 6Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 7Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 8Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 9Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 10Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 11Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 12Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 13Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 14Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 15Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 16Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 17Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 18Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 19
GELase 50X Reaction Buffer from EPICENTRE Biotechnologies
Rat Anti-Mouse Macrophages, Metallophilic Monoclonal Antibody, Unconjugated from AbD Serotec
BMP-2 ELISA Kit from R&D Systems
Argarase from BioVision
Biology Products: